Abbott Laboratories: It's No Longer A Buy For Now
Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are neutral on ABT stock.
Is Abbott Laboratories Stock a Buy?
If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing in Abbott Laboratories (NYSE: ABT). Abbott is a longtime leader in the healthcare sector, and has generally delivered excellent returns to long-term shareholders.
Abbott Labs board OKs $7 billion stock buyback program
Medical device giant Abbott Laboratories is launching a $7 billion stock buyback program. The repurchase of common shares was approved by Abbott’s board of directors this month, the North Chicago-based company announced today in conjunction with revealing its third-quarter earnings.
Abbott Laboratories (ABT) Gets a Buy from Piper Sandler
In a report released today, Adam Maeder from Piper Sandler maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a
Abbott Laboratories 3Q Sales Top Expectations
Abbott Laboratories posted better-than-expected sales in its latest quarter, which it attributed to strong underlying base business performance. The healthcare-products manufacturer logged earnings of $1.
Why Abbott Laboratories Stock Was a Winner on Wednesday
Investors happily greeted the latest news from Abbott Laboratories (NYSE: ABT) on Hump Day. After the storied healthcare company unveiled its third-quarter results, those folks traded its stock up by 1.
MarketWatch3h
Abbott Laboratories stock underperforms Thursday when compared to competitors despite daily gains
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Abbott Labs Path To Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic
On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating ...
Abbott Laboratories: Strong Buy Rating Driven by Robust Growth Prospects and Operational Improvements
Bernstein analyst Lee Hambright maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target ...
Abbott Narrows 2024 Forecast as Diabetes Devices Drive Sales
Abbott Laboratories narrowed its full-year profit outlook, raising the midpoint slightly, as strong demand for its diabetes ...
Abbott bumps up profit forecast on strong medical device sales
Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...
Abbott Laboratories: Buy Rating Reaffirmed Amid Strong Medical Device Performance and Positive Long-Term Growth Outlook
Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price ...
Abbott Slightly Raises Profit Forecast on Strong Medical Device Sales
(Reuters) - Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates ...
High-Quality Abbott Stock: Corporate Growth That Pays You to Own It
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...
Abbott Laboratories: Balanced Prospects Lead to Hold Recommendation Amid Market Adjustments
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...